# Ensysce Biosciences Inc. (ENSC)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $649,573.784  
**Price:** $0.25

> Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company developing prescription therapeutics for severe pain and central nervous system conditions, including ADHD and opioid use disorder. It leverages two proprietary prodrug platforms: TAAP™ (Trypsin-Activated Abuse Protection), which modifies active ingredients like oxycodone or amphetamine to remain inactive until exposed to trypsin in the small intestine, deterring tampering, injection, snorting, or chewing; and MPAR® (Multi-Pill Abuse Resistance), which incorporates a controlled-release trypsin inhibitor to limit active drug release in overdose scenarios, providing built-in protection. Lead programs include PF614, a TAAP™ extended-release oxycodone analogue in Phase 3 trials for post-surgical pain; PF614-MPAR, combining both platforms with FDA Breakthrough Therapy designation; PF8026 and PF8001 for ADHD; and PF9001 for opioid use disorder. These innovations aim to deliver effective analgesia and therapies while minimizing abuse, dependence, and overdose risks. Headquartered in La Jolla, California, Ensysce Biosciences Inc. operates in the pharmaceutical preparation manufacturing sector, focusing on tamper-resistant oral medications.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $5M | — | -$10M | — | $-3.98 |
| 2024 | $5M | — | -$7M | — | $-11.45 |
| 2023 | $2M | — | -$11M | — | $-70.40 |
| 2022 | $3M | — | -$24M | — | $-139.42 |
| 2021 | $4M | — | -$20M | — | $-1.48 |
| 2020 | $4M | — | -$2M | $4M | $0.00 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7M | $5M | $3M | $4M | — |
| 2024 | $6M | $2M | $4M | $4M | — |
| 2023 | $3M | $3M | -$322,858 | $1M | — |
| 2022 | $6M | $10M | -$4M | $3M | — |
| 2021 | $16M | $25M | -$8M | $12M | — |
| 2020 | $351,807 | $7M | -$6M | $194,214 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$8M | $123,643 | -$8M |
| 2024 | -$8M | — | — |
| 2023 | -$11M | — | — |
| 2022 | -$18M | — | — |
| 2021 | -$8M | — | — |
| 2020 | -$1M | — | — |
| 2019 | -$1M | — | — |
| 2018 | -$1M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ENSC)